Abstract
Over the last ten years, the treatment of seronegative spondyloarthropathies has changed dramatically with the introduction of the anti-tumor necrosis factor alpha (TNFα) agents. Nevertheless, there is a growing number of studies describing several adverse reactions in patients treated with biological agents. In the present report we describe the case of a 22-year-old male patient with ankylosing spondylitis who developed a "paradoxic" adverse reaction, while receiving infliximab.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal / therapeutic use
-
Arthritis / blood
-
Arthritis / chemically induced*
-
Fever / chemically induced
-
Humans
-
Immunosuppressive Agents / administration & dosage
-
Immunosuppressive Agents / adverse effects*
-
Immunosuppressive Agents / therapeutic use
-
Infliximab
-
Male
-
Methotrexate / administration & dosage
-
Methotrexate / therapeutic use
-
Spondylitis, Ankylosing / blood
-
Spondylitis, Ankylosing / drug therapy*
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
-
Young Adult
Substances
-
Antibodies, Monoclonal
-
Immunosuppressive Agents
-
Tumor Necrosis Factor-alpha
-
Infliximab
-
Methotrexate